Dr. Michel Lebel PhD is a full professor in the Department of Molecular Biology, Medical Biochemistry, and Pathology at Laval University. Dr. Lebel obtained his PhD from Université de Montréal and completed post-doctoral studies in the Department of Genetics at Harvard Medical School. He has been an independent investigator since 2000 at the Centre de Recherche du CHU de Québec. His research focuses on deciphering the molecular and cellular events leading to premature aging in a mouse model of Werner syndrome. Press releases on the results of his work have been published by the Science Daily news, the National Post, Medical News Today, the Montreal Gazette, and the Nutraceuticals World online magazine. He was interviewed by the CBC radio (107,7 FM) on January 11th, 2010 and by the Journal de Québec on September 30th, 2012 (Le vieillissement, plus qu’une affaire de gènes).
Since the middle of the last century, improvements in healthcare have increased human life expectancy. However, we are now facing the new challenge and paradox of an older population with increased longevity, but often still with many years of poor health or disability ahead of them. A better understanding of the mechanisms leading to the decline in function with age would provide new predictive biomarkers and potential therapeutic targets. It is now clear that each person’s genetic code has a significant influence on the aging process. The main goal of Dr. Lebel’s research is to understand why a slight modification of certain genes precipitates the onset of age-related diseases, and to identify key biological factors leading to the onset of these diseases. In addition, using cutting-edge technologies, his team is working to understand how vitamin C and other natural products may prevent age-related diseases in humans. To do this, Dr. Lebel is studying a mouse model of a human genetic disorder called Werner syndrome, characterized by premature aging in affected patients. Finally, Dr. Lebel’s laboratory is also working to identify key proteins in the blood that would help diagnose cancer more quickly in patients.
2705, boulevard Laurier
Canada G1V 4G2
Data not available
An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells.Journal Article
Cancer Sci, 102 (7), pp. 1410-7, 2011, ISSN: 1347-9032.
Proteome-wide identification of WRN-interacting proteins in untreated and nuclease-treated samples.Journal Article
J Proteome Res, 10 (3), pp. 1216-27, 2011, ISSN: 1535-3893.
Resveratrol improves insulin resistance hyperglycemia and hepatosteatosis but not hypertriglyceridemia, inflammation, and life span in a mouse model for Werner syndrome.Journal Article
J Gerontol A Biol Sci Med Sci, 66 (3), pp. 264-78, 2011, ISSN: 1079-5006.
The Werner syndrome helicase protein is required for cell proliferation, immortalization, and tumorigenesis in Scaffold attachment factor B1 deficient mice.Journal Article
Aging (Albany NY), 3 (3), pp. 277-90, 2011, ISSN: 1945-4589.
Metabolism, genomics, and DNA repair in the mouse aging liver.Journal Article
Curr Gerontol Geriatr Res, 2011 , pp. 859415, 2011, ISSN: 1687-7063.
Mitochondrial dysfunction in some oxidative stress-related genetic diseases: Ataxia-Telangiectasia, Down Syndrome, Fanconi Anaemia and Werner Syndrome.Journal Article
Biogerontology, 11 (4), pp. 401-19, 2010, ISSN: 1389-5729.
Ascorbate improves metabolic abnormalities in Wrn mutant mice but not the free radical scavenger catechin.Journal Article
Ann N Y Acad Sci, 1197 , pp. 40-4, 2010, ISSN: 0077-8923.
Depletion of WRN protein causes RACK1 to activate several protein kinase C isoforms.Journal Article
Oncogene, 29 (10), pp. 1486-97, 2010, ISSN: 0950-9232.
Werner's syndrome helicase participates in transcription of phenobarbital-inducible CYP2B genes in rat and mouse liver.Journal Article
Biochem Pharmacol, 79 (3), pp. 463-70, 2010, ISSN: 0006-2952.
Vitamin C restores healthy aging in a mouse model for Werner syndrome.Journal Article
FASEB J, 24 (1), pp. 158-72, 2010, ISSN: 0892-6638.
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Cibler l’instabilité génomique en tant que vulnérabilité essentielle du cancer de l’ovaire, Subvention, Fonds de recherche du Québec - Santé, ONCOPOLE EMC2: Équipes multi-institutionnelles contre le cancer, from 2018-05-01 to 2021-04-30
Recently finished projects
- Soutien au projet de recherche dans l'axe endocrinologie et néphrologie, Subvention, Fondation du CHU de Québec, from 2020-02-19 to 2020-03-31